R. Romiti, P. Pancheri - Vol. 5, Giugno 1999, num.2
Testo Immagini Bibliografia Summary Riassunto Indice
Le depressioni moderate a componente
ansiosa:
un target terapeutico specifico per venlafaxina a Rilascio
Moderate depression with an ansious component:
a specific therapeutic target for venlafaxine-extended
Venlafaxine blocks both serotonin (5-HT) and noradrenaline (NA) transporters, with a higher affinity for the former and a 5-HT/NA re-uptake blockade ratio that varies with increasing doses. Recently, an extended-relase drug formulation was developed and tested with the following aims: increase safety, enhance the efficacy spectrum, and facilitate dosing. Drug trials showed plasma concentration and time to peak plasma levels to ensure tolerance and efficacy in depression associated with anxiety as well as in specific anxiety disorders.
The tolerance and safety profiles of venlafaxine XR showed thie formulation to have similar side effects to most SSRIs and a better tolerance with respect to the immediate release formulation.
On the basis of recent controlled studies, the US Food and Drug Administration (FDA) approved venlafaxine with the indication for the treatment of generalised anxiety disorder and this is the first time an antidepressant is granted approval for such indication.